Effect of pyrrolizidine alkaloids from tansy ragwort (senecio jacobaea) on hepatic drug-metabolizing enzymes in male rats.

C. Miranda,P. Cheeke,D. Buhler

DOI: https://doi.org/10.1016/0006-2952(80)90080-5

IF: 6.1

1980-10-01

Biochemical Pharmacology

Abstract:

What problem does this paper attempt to address?

Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones

Minnie Malik,Joy Britten,Jeris Cox,Amrita Patel,William H Catherino

DOI: https://doi.org/10.1016/j.fertnstert.2015.09.006

Abstract:Objective: To determine the effect of GnRH analogues (GnRH-a) leuprolide acetate (LA) and cetrorelix acetate on gonadal hormone-regulated expression of extracellular matrix in uterine leiomyoma three-dimensional (3D) cultures. Design: Laboratory study. Setting: University research laboratory. Patient(s): Women undergoing hysterectomy for symptomatic leiomyomas. Intervention(s): The 3D cell cultures, protein analysis, Western blot, immunohistochemistry. Main outcome measure(s): Expression of extracellular matrix proteins, collagen 1, fibronectin, and versican in leiomyoma cells 3D cultures exposed to E2, P, LA, cetrorelix acetate, and combinations for 24- and 72-hour time points. Result(s): The 3D leiomyoma cultures exposed to E2 for 24 hours demonstrated an increased expression of collagen-1 and fibronectin, which was maintained for up to 72 hours, a time point at which versican was up-regulated significantly. Although P up-regulated collagen-1 protein (1.29 ± 0.04) within 24 hours of exposure, significant increase in all extracellular matrix (ECM) proteins was observed when the gonadal hormones were used concomitantly. Significant decrease in the amount of ECM proteins was observed on use of GnRH-a, LA and cetrorelix, with 24-hour exposure. Both the compounds also significantly decreased ECM protein concentration despite the presence of E2 or both gonadal hormones. Conclusion(s): This study demonstrates that GnRH-a directly affect the gonadal hormone-regulated collagen-1, fibronectin, and versican production in their presence. These findings suggest that localized therapy with GnRH-a may inhibit leiomyoma growth even in the presence of endogenous gonadal hormone exposure, thereby providing a mechanism to eliminate the hypoestrogenic side effects associated with GnRH-a therapy.
Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas

Andrea Di Lieto,Marianna De Falco,Fabrizio Pollio,Gelsomina Mansueto,Gaetano Salvatore,Pasquale Somma,Francesca Ciociola,Gaetano De Rosa,Stefania Staibano

DOI: https://doi.org/10.1016/j.jsgi.2004.10.008

Abstract:Objective: Basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) are involved in the pathogenesis of leiomyomas and influence angiogenesis, which is necessary for growth of leiomyomas. Gonadotropin-releasing hormone analogue (GnRH-a) treatment might modify the growth factor expression and the blood supply in myomas. We investigated the effects of GnRH-a treatment on some clinical parameters, on the immunohistochemical expression of bFGF, VEGF, and PDGF, and on the vasculature of leiomyomas. Methods: Thirty-one women were treated with leuprolide acetate for 3 months; 55 untreated patients formed the control group. Hematologic parameters were assessed at the admission, after GnRH-a treatment, and after surgery. Uterine volume was evaluated by ultrasonography. The immunoexpression of bFGF, VEGF, and PDGF and of the endothelial markers CD34 and CD105, as well as the vascular pattern, were studied in leiomyomas, comparing treated and untreated patients. Results: Hematologic parameters improved and uterine volumes decreased after GnRH-a treatment. The immunoexpression of bFGF, VEGF, and PDGF decreased in treated myomas, together with the total number of vessels and the angiogenetic vessels. Conclusion: This study confirms the clinical response of uterine shrinkage after GnRH-a treatment. A pathogenetic role of bFGF, VEGF, and PDGF in myoma growth and vascularization is suggested. Finally, this study indirectly confirms the importance of the vasculature in leiomyoma growth.
Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment

F Ito,N Kawamura,T Ichimura,A Tsujimura,O Ishiko,S Ogita

DOI: https://doi.org/10.1016/s0015-0282(00)01660-5

Abstract:Objective: To compare ultrastructural features of leiomyoma cells from the same uterine myoma nodule before and after GnRH agonist (GnRH-a) treatment and to examine the relation between these ultrastructural changes and the extent of myoma volume reduction with GnRH-a treatment. Design: Prospective clinical study. Setting: University teaching hospital. Patient(s): Twenty women with uterine leiomyomas who were scheduled for surgery. Intervention(s): Transcervical needle biopsy of uterine myoma, s.c. leuprolide acetate injection (3.75 mg) at least three times every 4 weeks before surgery, and hysterectomy or myomectomy. Main outcome measure(s): The changes in ultrastructural features of uterine leiomyoma cells and the percentage decrease in the volume of the largest myoma at 12 weeks of GnRH-a treatment measured by magnetic resonance imaging. Result(s): A decrease in myofilaments, mitochondrial swelling, and emergence of the lysosomal body were observed in relation to GnRH-a treatment. Furthermore, a positive correlation was observed between the decrease in myofilaments and myoma shrinkage. Conclusion(s): Cellular atrophy due to a decrease in myofilaments plays a major role in the reversible myoma shrinkage resulting from GnRH-a treatment.
Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas

Masato Nakayama,Tomoko Mitsuhashi,Yoshihiko Shimizu,Osamu Ishihara,Michio Shimizu

DOI: https://doi.org/10.1111/j.1440-1827.2008.02222.x

Abstract:Gonadotropin-releasing hormone agonist (GnRH-a) therapy is frequently applied to reduce the volume of uterine leiomyomas (UL). In addition, the possible relationship between mast cells (MC) within UL and the development of UL has been suggested, but the role of MC in UL remains to be determined. UL with or without GnRH-a therapy in 121 premenopausal patients were reviewed. The number of MC was evaluated between the two groups, immunohistochemistry was done for insulin-like growth factor-I (IGF-I), and the association between the IGF-I immunoreactivity in UL and the GnRH-a therapy was analyzed. The number of MC significantly increased in UL in GnRH-a therapy, while IGF-I immunoreactivity was significantly reduced in smooth muscle cells of these UL. Furthermore, IGF-I immunoreactivity in MC was inversely correlated with the size reduction rate of UL in GnRH-a therapy. Although GnRH-a therapy is considered to reduce the size of UL transiently, the regression of UL was in part hampered by the increased IGF-I secretion from the increased MC after GnRH-a therapy. Therefore, the more the IGF-I secretion from MC in UL increases, the less effective the GnRH-a therapy is on the size reduction of UL. Thus, the present study may provide an explanation of the possible mechanism of GnRH-a resistance in UL.
N-Acetylcysteine enhances UV-mediated caspase-3 activation, fragmentation of E2F-4, and apoptosis in human C8161 melanoma: inhibition by ectopic Bcl-2 expression.

M. Rieber,M. Rieber

DOI: https://doi.org/10.1016/S0006-2952(03)00147-3

IF: 6.1

2003-05-15

Biochemical Pharmacology

Abstract:
Effects of gonadotropin-releasing hormone agonists on uterine volume and vasculature and on the immunohistochemical expression of basic fibroblast growth factor (bFGF) in uterine leiomyomas

A Di Lieto,M De Falco,S Staibano,F Iannotti,M Scaramellino,G Salvatore,G Mansueto,P Granata,M Pontillo,F Pollio,G De Rosa

DOI: https://doi.org/10.1097/01.PGP.0000070849.25718.73

Abstract:We investigated the effect of the GnRH agonist (GnRH-a) on the uterine volume and on the immunohistochemical expression of basic fibroblast growth factor (bFGF) and the vasculature of leiomyomas. Twenty-five women were treated with leuprorelin acetate for 3 months; 46 untreated patients were enrolled as a control group. The uterine volume was measured by ultrasonography. After myomectomy or hysterectomy, the immunoexpression of bFGF and the endothelial marker, CD34, was studied and compared in treated and untreated leiomyomas. Uterine volume decreased after therapy. The number of cells expressing bFGF and the vascularity were diminished in treated leiomyomas. Reduction in the blood supply might be responsible, in part, for uterine-volume shrinkage after GnRH-a therapy.
Twenty-fifth annual national meeting of the reticuloendothelial society.

G. Virella,H. Fudenberg

DOI: https://doi.org/10.1016/0090-1229(79)90134-X

1979-09-01

Clinical Immunology and Immunopathology

Abstract:
Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor

Marianna De Falco,Stefania Staibano,Francesco Paolo D'Armiento,Massimo Mascolo,Gaetano Salvatore,Anna Busiello,Ilma Floriana Carbone,Fabrizio Pollio,Andrea Di Lieto

DOI: https://doi.org/10.1016/j.jsgi.2006.02.008

Abstract:Objective: To evaluate the clinical features and the expression of transforming growth factor-beta3 (TGF-beta3) and connective tissue growth factor (CTGF) in myometrium and uterine leiomyomas after preoperative treatment with gonadotropin-releasing hormone-analogs (GnRH-a) and tibolone. Methods: Twenty-three patients received 3.75 mg leuprolide acetate depot for 4 months. Twenty-two patients received the same therapy plus 2.5 mg tibolone daily. Patients underwent uterine surgery after therapy. Twenty-two untreated patients underwent surgery directly. Hematologic tests, bone mineral density (BMD) measurement, and ultrasonographic evaluation of uterine volume were performed before and after treatment. Menorrhagia and pelvic pain were evaluated with a visual analog scale. Hot flushes were recorded in daily diaries. Immunohistochemical expression of TGF-beta3 and CTGF in myometrium and myoma samples was evaluated semiquantitatively. Results: After therapy, hemoglobin and iron levels similarly increased in both groups. BMD significantly decreased only in the GnRH-a group. Uterine volume similarly decreased in both groups. No patient had menorrhagia or pelvic pain at the end of therapy. The number of hot flushes increased after the first month in the GnRH-a group; in the GnRH-a plus tibolone group, it remained constant and was lower. In untreated cases, TGF-beta3 and CTGF smooth muscle cell immunoexpression was lower in myometrium than in leiomyomas. After medical treatment, growth factor immunoexpression remained unchanged in myometrial samples and was reduced in leiomyomas. Endothelial cells showed strong immunopositivity, both in untreated and in treated cases. Conclusion: This study focuses on the effects of GnRH-a and tibolone on TGF-beta3 and CTGF expression in myometrium and myomas and supports the hypothesis of a pathogenetic role of these growth factors in uterine fibromatosis.
The hemodynamic effect of GnRH agonist therapy on uterine leiomyoma vascularity: a prospective study using transvaginal color Doppler sonography

F A Aleem,M Predanic

DOI: https://doi.org/10.3109/09513599509160454

Abstract:The objective of this study was to correlate, during 12 weeks of therapy with gonadotropin releasing hormone agonist (GnRH-a), the chronological effect and the hemodynamic changes on the uterine artery and the leiomyometrial supplying vessels. Twenty-three premenopausal women with clinically diagnosed uterine leiomyomas received 3.75 mg of leuprolide acetate intramuscularly every 4 weeks for 12 weeks. Pretreatment values of serum estradiol, uterine and leiomyoma volumes and blood flow characteristics of the main uterine artery and leiomyoma supplying vessels-resistance index (RI), pulsatility index (PI) and peak-systolic velocity, obtained by transvaginal color Doppler sonography-were compared with treatment values at 4, 8 and 12 weeks of leuprolide acetate therapy. The first event in the chronological response to the GnRH-a therapy was a statistically significant increase in RI and PI values for major leiomyoma vessels, observed at the end of the 4th week (p < 0.05), which increased significantly after 8 and 12 weeks (p < 0.01 and p < 0.001, respectively). These findings were in direct correlation with a significant decrease of estradiol levels after 4, 8 and 12 weeks (p < 0.05, p < 0.001 and p < 0.001, respectively). The significant decrease of blood flow in the leiomyometrial vessels was followed by a significant decrease of the main uterine artery blood flow after 8 weeks and uterine and leiomyoma volumes by 42% and 55%, respectively, after 12 weeks of GnRH-a therapy. We concluded that a significant increase in leiomyometrial vessels RI and PI values, which was found 4 weeks after the first dose of GnRH-a, but without major leiomyoma volume decrease, emphasizes that the first significant effect of GnRH therapy in the process of uterine and leiomyoma volume shrinkage is the reduction of leiomyometrial rather than uterine blood flow. This effect is followed by a considerable reduction of uterine vascularity and a significant decrease of uterine and leiomyoma volumes. If a decrease of blood loss during myomectomy is the main aim of GnRH-a therapy, we believe that 8 weeks would be an appropriate therapy duration.
Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy

Khaleque Newaz Khan,Michio Kitajima,Koichi Hiraki,Akira Fujishita,Ichiro Sekine,Tadayuki Ishimaru,Hideaki Masuzaki

DOI: https://doi.org/10.1093/humrep/dep437

Abstract:Background: Information is limited regarding the multifunctional role of GnRH agonist (GnRHa) therapy in reproductive diseases. We investigated the pattern of changes in inflammatory reaction, micro-vessel density and apoptosis in the tissues collected from women with endometriosis, adenomyosis and uterine myoma who were treated with or without GnRHa therapy. Methods: Biopsy specimens were collected from lesions, myometria and corresponding endometria of 45 women with ovarian endometrioma, 35 women with adenomyosis and 56 women with uterine myoma. A fraction of these women were treated with GnRHa therapy for a variable period of 3-6 months before surgery. We performed immunohistochemical analysis of CD68, a macrophage (Mvarphi) marker and von Willebrand factor (VWF), a vessel marker, using respective antibodies. Changes in apoptosis were examined using TdT-mediated dUTP-biotin nick end-labeling assay and by the immunoexpression of activated caspase-3 in tissues after GnRHa therapy. Results: The infiltration of CD68-positive Mvarphi and VWF-positive micro-vessel density were significantly decreased in the endometria of women with endometriosis, adenomyosis and uterine myoma in the GnRHa-treated group when compared with that in the non-treated group. Marked decreases in inflammatory and angiogenic responses were observed in lesions and myometria of these diseases. When compared with the non-treated group, a significant increase in apoptotic index (apoptotic cells per 10 mm(2) area) and quantitative-histogram scores of activated caspase-3 after GnRHa therapy were observed in the eutopic endometria, lesions and myometria of these diseases. Conclusions: GnRHa was able to markedly reduce the inflammatory reaction and angiogenesis and to significantly induce apoptosis in tissues derived from women with endometriosis, adenomyosis and uterine myoma. These multiple biological effects at the tissue level may be involved in the regression of these reproductive diseases.
In the long-run we are all dead: on the benefits of peer punishment in rich environments

Dirk Engelmann,N. Nikiforakis

DOI: https://doi.org/10.1007/s00355-015-0884-5

2015-03-07

Social Choice and Welfare

Abstract:
Involvement of parathyroid hormone-related peptide in cell proliferation activity of human uterine leiomyomas

M Yoshida,A Ohtsuru,T Samejima,M Okazaki,A Fujishita,M Ito,S Yamashita,T Ishimaru

DOI: https://doi.org/10.1507/endocrj.46.81

Abstract:Uterine leiomyomas develop from uterine smooth muscle cells, which are known to be regulated by estrogen and other growth factors. The purpose of this study was to investigate the role of expression of parathyroid hormone related-peptide (PTHrP) in the growth of uterine leiomyomas treated or untreated with gonadotropin-releasing hormone agonist (GnRH-a). Thirty-nine leiomyoma tissues were obtained from 36 patients who had been treated with GnRH-a (n=10) or without GnRH-a (n=29). The intensity of PTHrP immunostaining was categorized into three grades; "negative", "weakly positive", and "positive". Leiomyoma cell growth was estimated by the proliferating cell nuclear antigen (PCNA) labeling index (LI) with an image analyser. We also investigated the correlation between PTHrP expression and cell proliferation or histopathological findings. In the GnRH-a-untreated group, LI of the PTHrP "positive" group was significantly higher than that of the PTHrP "negative" group, but the intensity of PTHrP immunostaining did not correlate with LI in the GnRH-a-treated group. PTHrP expression did not correlate with histological findings or clinical parameters (age and phase of menstrual cycle) in either the GnRH-a-treated or the -untreated group. In addition, the expression of mRNA for PTHrP and its receptor was detected in leiomyomas by reverse transcriptase-polymerase chain reaction (RT-PCR). Our results indicate that the expression of PTHrP in leiomyomas correlated positively with cell growth in the GnRH-a-untreated group, suggesting that PTHrP may act as a local cell growth modifier in an autocrine/paracrine fashion on uterine leiomyomas.
Chronic Medroxyprogesterone Acetate (mpa) Treatment of Human Endometrial Stromal Cells Inhibits Chemokine Gene Expression.

D Zhao,DI Lebovic,D Hornung,RN Taylor

DOI: https://doi.org/10.1016/s0015-0282(01)02205-1

IF: 6.7

2001-01-01

Fertility and Sterility

Abstract:Objective: It has been proposed that an inflammatory reaction is responsible for the pelvic pain associated with endometriosis. Our laboratory has studied the role of the monocyte chemokine, RANTES (Regulated on Activation, Normal T-cell Expressed and Secreted), as a mediator of this immune response. We hypothesized that the symptomatic relief observed after MPA treatment is associated with inhibition of RANTES gene expression in endometrial stromal cells. Design: Luciferase analysis of chemokine gene promoter and western blot analysis of progesterone receptor in primary human endometrial stromal cell cultures. Materials/Methods: Primary human endometrial stromal cells were prepared and cultured in the absence or presence of up to 100 nM MPA for 2 days (acute treatment) or 8 days (chronic treatment). Human RANTES promoter-luciferase reporter constructs were transiently transfected using previously established conditions that afford a >40% transfection rate. For data normalization and to assure consistent transfection efficiency an internal standard plasmid (renilla luciferase reporter) was co-transfected. Data are expressed as mean ± SD for at least 3 independent experiments and were compared using nonparametric Mann-Whitney statistics. The presence of PR (progesterone receptors) was verified by western blot. Results: Acute treatment (2 days) with 100 nM MPA had no effect on RANTES transcriptional activation. However, in endometrial cells cultured with 100 nM MPA for 8 days, RANTES promoter activation was decreased by 39 ± 17% (p < 0.01). Chronic treatment with MPA increased the two isoforms, PR-A and PR-B in stromal cells, while acute treatment had little effect on receptor concentration. Conclusions: These results provide evidence that chronic, but not acute, progestin-induced changes in endometrial stromal cells result in decreased RANTES gene expression. The presence of PR is consistent with a PR-mediated effect of MPA. This in vitro finding may represent an anti-inflammatory effect in vivo, in part responsible for the amelioration of subjective endometriosis symptoms in women using chronic progestins. Supported By: NIH/NICHD Specialized Cooperative Centers Program in Reproduction Research (U54HD37321).
Effect of Monocyte/macrophages Activated by CpG -Oligodeoxynucleotides of Bacteria on K562 Cells

CHEN Chun-yan,WANG Hong-yan,CAO Qian,XIAO Ying,WANG Lin-lin,ZHANG Rong-mei,JIA Ji-hui

DOI: https://doi.org/10.3321/j.issn:1000-4718.2007.05.034

2007-01-01

Abstract:AIM: To study the effect of monocyte/macrophages treated with CpG-oligodeoxynucleotides on leukemic K562 cells. METHODS: The monocytes/macrophages from peripheral blood cells were isolated and induced. The expressions of CD14 and CD16 on monocytes/macrophages were detected by means of flow cytometry. After treated with synthetic CpG-oligodeoxynucleotides, and nonCpG-oligodeoxynucleotides for 24 hours respectively, the inhibiting effect of monocyte/macrophages on K562 cells were detected using MTT method. The secretions of TNF-α and IL-12 from monocytes/macrophages were determined using ELISA method. RESULTS: The monocytes/macrophages treated with CpG-oligodeoxynucleotides enhanced their antitumor effect on K562 cells and increased the secretion levels of TNF-α and IL-12. Whereas, there was no significant difference between antitumor effect and cytokine secretion of the monocytes/macrophages treated with nonCpG-oligodeoxynucleotide. CONCLUSION: CpG-oligodeoxynucleotides increases the cytotoxicity of macrophages on K562 cells in vitro, as well as facilitates the IL-12 and TNF-α secretion. It provides a new approach for immunologic treatment of leukemia.
Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes

Marianna De Falco,Stefania Staibano,Massimo Mascolo,Chiara Mignogna,Luigi Improda,Francesca Ciociola,Ilma F Carbone,Andrea Di Lieto

DOI: https://doi.org/10.1016/j.ejogrb.2009.02.006

Abstract:Objective: To evaluate if pre-operative GnRH-a modify uterine leiomyoma pseudocapsule and the possible clinical effects of these changes. Study design: The study was performed at the University Federico II of Naples on 33 premenopausal patients submitted to laparotomic myomectomy after treatment with triptorelin depot. 29 untreated patients formed the control group. The operating time, the intraoperative bleeding and the prompt identification of the cleavage plan between myoma and myometrium were evaluated. The pseudocapsule features and the immunoexpression of PCNA and CD34 in this area were studied. Results: Treated patients showed lower blood loss and not clearly identifiable cleavage plan, but without any significant increase in the operating time. Treated lesions showed less evident border between myoma and myometrium and lower PCNA and CD34 pseudocapsule immunoexpression than untreated ones. Conclusion: We propose the changes of leiomyoma pseudocapsule as partial explanations of the reported clinical and surgical findings after pre-operative GnRH-a.
[Use of nonionic contrast media in computerized tomography].

M. Langer,R. Felix,B. Behrends,H. Eichstädt

1987-03-01

Abstract:In a prospective multicentre study of 4,970 contrast enhanced CT's with intravenous application of lohexol, no contrast medium induced side effects could be diagnosed in 98.4% of the patients. Patients with a positive history of allergic diathesis had an increased risk of unexpected contrast-medium induced systemic reactions (factor 2 to 3). In 21% the diagnosis could not be established by non-enhanced CT alone, whereas in 56% the diagnostic accuracy was improved by intravenous contrast medium injection.
Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system

Takeshi Maruo,Noriyuki Ohara,Shigeki Yoshida,Koji Nakabayashi,Hiroko Sasaki,Qin Xu,Wei Chen,Hideto Yamada

DOI: https://doi.org/10.1016/j.contraception.2010.05.006

IF: 3.051

Contraception

Abstract:The use of levonorgestrel-releasing intrauterine system (LNG-IUS) is effective for management of menorrhagic women with uterine myomas because of reduction in menorrhagia. However, the size of myomas during use of LNG-IUS increased in some but decreased in other instances. This prompted us to characterize the effects of progesterone (P4) on cultured leiomyoma cell growth. Treatment with P4 resulted in increase in epidermal growth factor (EGF) expression in cultured leiomyoma cells, whereas treatment with E2 augmented EGF-R expression in those cells. This indicates that P4 and E2 act in combination to stimulate myoma growth through induction of EGF/EGF-R expression. Bcl-2 expression in leiomyoma cells was up-regulated by P4. Furthermore, P4 augmented proliferating cell nuclear antigen expression in cultured leiomyoma cells but not in cultured normal myometrial cells. This fact let us to examine the effects of progesterone receptor modulator (PRM) on leiomyoma cell proliferation and apoptosis in comparison with normal myometrial cells. Our studies revealed that CDB-2914 inhibits the proliferation, stimulates apoptosis of cultured leiomyoma cells, and inhibits the expression of angiogenic factors (vascular endothelial growth factor and adrenomedullin) and their receptors in cultured leiomyoma cells, without affecting those in cultured normal myometrial cells. We then evaluated the effects of CDB-2914 on extracellular matrix (ECM) components in cultured leiomyoma cells. CDB-2914 increased ECM metalloproteinase inducer, matrix metalloproteinase (MMP)-1, MMP-8 contents and decreased tissue inhibitors of MMP (TIMP)-1, TIMP-2 contents as well as type I and type III collagen contents in cultured leiomyoma cells, without comparable effects on cultured normal myometrial cells. These findings demonstrate that PRM not only inhibits the proliferation and stimulates apoptosis of cultured leiomyoma cells but also suppresses collagen synthesis in a cell-type specific manner. This is meaningful for understanding the molecular mechanism of the usefulness of PRM in the treatment of uterine fibroids.
Prolonged Gonadotropin-Releasing Hormone Agonist Therapy Reduced Expression of Nitric Oxide Synthase in the Endometrium of Women with Endometriosis and Infertility

JH Wang,FZ Zhou,MY Dong,RJ Wu,YL Qian

DOI: https://doi.org/10.1016/j.fertnstert.2005.09.028

2005-01-01

Abstract:Objective: To determine whether endometrial expression of endothelial nitric oxide synthase (eNOS) or inducible NOS (iNOS) protein in women with endometriosis-associated infertility is different from that in the fertile controls, whether GnRH agonist (GnRH-a) regulates the endometrial expression of NOS in women with endometriosis-associated infertility, and whether there is a correlation between serum E, or P levels, and the endometrial expression of eNOS or iNOS.Design: Prospective controlled Study.Setting: University hospital for reproductive medicine and gynecologic endocrinology.Patient(s): Thirty patients with endometriosis-associated infertility and 19 patients with carcinoma in situ of the cervix.Intervention(s): Endometrial biopsy specimens and blood samples.Main Outcome Measure(s): Endometrial eNOS and iNOS protein relative levels and serum concentrations of E, or P.Result(s): By Western blot analysis, iNOS was not detected, and a unique menstrual cycle-dependent expression of eNOS was observed. Eutopic endometrium in women with endometriosis-associated infertility before GnRB-a treatment showed higher levels of eNOS than that of the control group. After 3 months of GnRH-a therapy, eNOS levels in the endometrium were reduced. In addition, a significant positive correlation was found between serum E-2 or P concentrations, and the endometrial expression of eNOS.Conclusion(s): The GnRH-a treatment attenuated the endometrial expression of eNOS in women with endometriosis-associated infertility. Endogenous ovarian steroids influence endometrial eNOS expression.
Experts' Encounters in Antenatal Diabetes Care: A Descriptive Study of Verbal Communication in Midwife-Led Consultations

Christina Furskog Risa,F. Friberg,Eva Lidén

DOI: https://doi.org/10.1155/2012/121360

2012-05-16

Nursing Research and Practice

Abstract:Aim. We regard consultations as cocreated communicatively by the parties involved. In this paper on verbal communication in midwife-led consultations, we consequently focus on the actual conversation taking place between the midwife and the pregnant woman with diabetes, especially on those sequences where the pregnant woman initiated a topic of concern in the conversation. Methods. This paper was undertaken in four hospital outpatient clinics in Norway. Ten antenatal consultations between midwives and pregnant women were audiotaped, transcribed to text, and analyzed using theme-oriented discourse analysis. Two communicative patterns were revealed: an expert's frame and a shared experts' frame. Within each frame, different communicative variations are presented. The topics women initiated in the conversations were (i) delivery, time and mode; (ii) previous birth experience; (iii) labor pain; and (iv) breast feeding, diabetes management, and fetal weight. Conclusion. Different ways of communicating seem to create different opportunities for the parties to share each other's perspectives. Adequate responses and a listening attitude as well as an ambiguous way of talking seem to open up for the pregnant women's perspectives. Further studies are needed to investigate the obstacles to, and premises for, providing midwifery care in a specialist outpatient setting.
Strong-Diameter Decompositions of Minor Free Graphs

Ittai Abraham,C. Gavoille,D. Malkhi,Udi Wieder

DOI: https://doi.org/10.1007/s00224-010-9283-6

2007-06-09

Abstract:

Effect of pyrrolizidine alkaloids from tansy ragwort (senecio jacobaea) on hepatic drug-metabolizing enzymes in male rats.

Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones

Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas

Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment

Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas

N-Acetylcysteine enhances UV-mediated caspase-3 activation, fragmentation of E2F-4, and apoptosis in human C8161 melanoma: inhibition by ectopic Bcl-2 expression.

Effects of gonadotropin-releasing hormone agonists on uterine volume and vasculature and on the immunohistochemical expression of basic fibroblast growth factor (bFGF) in uterine leiomyomas

Twenty-fifth annual national meeting of the reticuloendothelial society.

Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor

The hemodynamic effect of GnRH agonist therapy on uterine leiomyoma vascularity: a prospective study using transvaginal color Doppler sonography

Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy

In the long-run we are all dead: on the benefits of peer punishment in rich environments

Involvement of parathyroid hormone-related peptide in cell proliferation activity of human uterine leiomyomas

Chronic Medroxyprogesterone Acetate (mpa) Treatment of Human Endometrial Stromal Cells Inhibits Chemokine Gene Expression.

Effect of Monocyte/macrophages Activated by CpG -Oligodeoxynucleotides of Bacteria on K562 Cells

Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes

[Use of nonionic contrast media in computerized tomography].

Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system

Prolonged Gonadotropin-Releasing Hormone Agonist Therapy Reduced Expression of Nitric Oxide Synthase in the Endometrium of Women with Endometriosis and Infertility

Experts' Encounters in Antenatal Diabetes Care: A Descriptive Study of Verbal Communication in Midwife-Led Consultations

Strong-Diameter Decompositions of Minor Free Graphs